A clinical trial to compare atezolizumab plus chemotherapy with chemotherapy alone in people with triple-negative breast cancer (ALEXANDRA/IMpassion030/BIG 16-05/AFT-27).

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

Cancer
Breast Cancer
Triple Negative Breast Cancer

Results
Download

Study results

LPS WO39391 IMpassion030 Final Results February 2025 English (PDF, 0.8 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Argentina Spanish (PDF, 0.6 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Australia English (PDF, 0.8 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Austria German (PDF, 0.6 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Belgium Dutch (PDF, 0.5 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Belgium French (PDF, 0.6 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Belgium German (PDF, 0.6 MB)

LPS WO39391 IMpassion030 Final Results February 2025 China Chinese (PDF, 0.8 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Czech (PDF, 0.6 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Danish (PDF, 0.6 MB)

LPS WO39391 IMpassion030 Final Results February 2025 France French (PDF, 0.6 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Germany German (PDF, 0.6 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Hebrew (PDF, 0.6 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Hong Kong Chinese (PDF, 0.9 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Hungarian (PDF, 0.6 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Ireland English (PDF, 0.8 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Italy Italian (PDF, 0.5 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Japanese (PDF, 4.2 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Korean (PDF, 4.1 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Mexico Spanish (PDF, 0.5 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Peru Spanish (PDF, 0.5 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Polish (PDF, 0.6 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Portuguese (PDF, 0.5 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Romanian (PDF, 0.5 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Russian (PDF, 0.6 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Singapore Chinese (PDF, 4.2 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Spain Spanish (PDF, 0.5 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Switzerland French (PDF, 0.6 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Switzerland German (PDF, 0.6 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Switzerland Italian (PDF, 0.5 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Taiwan Chinese (PDF, 0.8 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Thai (PDF, 4.2 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Turkish (PDF, 0.5 MB)

LPS WO39391 IMpassion030 Final Results February 2025 Ukrainian (PDF, 0.6 MB)

What is Clinical Research?

In clinical research, volunteers, researchers, and medical professionals work together toward a shared goal: better treatment outcomes for patients. Clinical trials are vital to their process. They are carefully designed and follow approved protocols.

For the latest version of this information please go to www.forpatients.roche.com

Find participating medical centers and current study status in each of them

A clinical trial to compare atezolizumab plus chemotherapy with chemotherapy alone in people with triple-negative breast cancer (ALEXANDRA/IMpassion030/BIG 16-05/AFT-27).

For the latest version of this information please go to www.forpatients.roche.com